相关临床试验
178
39 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1954
进行中（未招募）
30
16.9%
已完成
70
39.3%
Enrolling By Invitation
5
2.8%
尚未招募
4
2.3%
招募中
35
19.7%
暂停
8
4.5%
终止
3
1.7%
Unknown
21
11.8%
撤回
2
1.1%
暂无批准数据
- NVG-291, an injectable peptide drug, demonstrated significant mobility improvements in a phase 2 trial for spinal cord injury patients, with one participant reducing his 10-meter walk time from 45 to 15 seconds. - The drug works by blocking inhibitory signals that prevent nerve fiber regrowth after spinal cord injury, potentially enhancing neuron growth and nervous system repair. - Patient Larry Williams continues to show sustained improvements over a year after completing the three-month treatment, including the ability to balance on one foot for 30 seconds. - Currently no FDA-approved treatments exist for spinal cord injuries, making this peptide approach a potentially significant breakthrough in neurological rehabilitation.
• NervGen Pharma will host a virtual investor event on April 9, 2025, featuring key opinion leaders to discuss the unmet medical needs and treatment landscape for spinal cord injury patients. • The company will present details of its Phase 1b/2a clinical trial evaluating NVG-291, a first-in-class therapeutic peptide targeting nervous system repair in both chronic and subacute spinal cord injury patients. • Clinical data from the double-blind, randomized, placebo-controlled trial is expected in the second quarter, with the study measuring corticospinal connectivity changes and motor function improvements as primary endpoints.
